Evaluation of apoptotic marker Bcl2, CD4+, human hepatocyte growth factor and metalloproteinase-9 as tumor markers for patients with hepatocellular carcinoma

被引：2
作者：
Youness E.R. [1 ]
El Nemr M. [2 ]
Oraby F.S. [1 ]
Ahmed N.M. [1 ]
Moghni M.A. [3 ]
Aly H.F. [4 ]
Ahmed H.H. [5 ]
机构：
[1] Medical Biochemistry Department, National Research Center, Dokki, Giza
[2] Internal Medicine Department, 6 October University, Cairo
[3] Internal Medicine Department, Ain Shams University, Cairo
[4] Therapeutic Chemistry Department, National Research Center, Dokki, Giza
[5] Hormones Department, National Research Center, Dokki, Giza
来源：
Indian Journal of Clinical Biochemistry | 2014年 / 29卷 / 3期
关键词：
HCC; HGF; MMP-9;
D O I：
10.1007/s12291-013-0381-5
中图分类号：
学科分类号：
摘要：
To examine the possible involvement of human B cell leukemia/lymphoma 2 (Bcl-2), CD4+ cells, hepatocyte growth factor (HGF), and metalloproteinase-9 (MMP-9), as biomarkers in early diagnosis of hepatocellular carcinoma (HCC), activities of these biomarkers in serum were demonstrated by the method of Enzyme Linked Immunosorbant Assay. Two groups of subjects (60 for each), were examined in this study; healthy controls and patients with HCC. The present results declare that, significant decrease in Bcl-2 (p ≤ 0.0001), and CD 4+ (p ≤ 0.001), while significant increase in HGF and MMP-9 (p ≤ 0.05). These findings imply an influence of these biomarkers by the existence of hepatic carcinoma that might reflect the progression of disease and a distinction between the pathological mechanisms involved in hepatic carcinoma. Since, the serum MMP-9 activity was significantly varied between each stage of HCC. An individual profile of the present investigated parameters was detected that might serve as an easy accessing serum marker to monitor the progression of hepatic cell disorders. © 2013 Association of Clinical Biochemists of India.
引用
收藏
页码：351 / 356
页数：5
相关论文
共 37 条
[21]  
Parmiani G., Anichini A.T., Cell infiltration and prognosis in HCC patients, J Hepatol, 45, pp. 178-181, (2006)
[22]  
Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, pp. 693-700, (1996)
[23]  
Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., Ansell S.M., Intratumoral CD4+ CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma, Blood, 107, pp. 3639-3646, (2006)
[24]  
Viguier M., Lemaitre F., Verola O., Cho M.-S., Gorochov G., Dubertret L., Bachelez H., Kourilsky P., Ferradini L., Foxp3 expressing CD4<sup>+</sup>CD25<sup>high</sup> regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells, Journal of Immunology, 173, 2, pp. 1444-1453, (2004)
[25]  
Parmiani G., Tumor-infiltrating T cells - Friend or foe of neoplastic cells?, New England Journal of Medicine, 353, 25, pp. 2640-2641, (2005)
[26]  
Yang X.H., Yamagiwa S., Ichida T., Matsuda Y., Sugahara S., Watanabe H., Sato Y., Abo T., Horwitz D.A., Aoyagi Y., Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma, J Hepatol, 45, pp. 254-262, (2006)
[27]  
Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., June C.H., Regulatory CD4<sup>+</sup>CD25<sup>+</sup> T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer, Cancer Research, 61, 12, pp. 4766-4772, (2001)
[28]  
Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., Kaiser L.R., June C.H., Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation, Journal of Immunology, 168, 9, pp. 4272-4276, (2002)
[29]  
Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nature Medicine, 10, 9, pp. 942-949, (2004)
[30]  
Unitt E., Rushbrook S.M., Marshall A., Davies S., Gibbs P., Morris L.S., Coleman N., Alexander G.J.M., Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells, Hepatology, 41, 4, pp. 722-730, (2005)
1234